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Abstract 34 
Systemic inflammation in end-stage renal disease (ESRD) is an established risk factor for mortality 35 
and a catalyst for other complications which are related to a premature aging phenotype, including 36 
muscle wasting, vascular calcification and other forms of premature vascular disease, depression, 37 
osteoporosis and frailty. Uremic inflammation is also mechanistically related to mechanisms involved 38 
in the aging process, such as telomere shortening, mitochondrial dysfunction, and altered  nutrient 39 
sensing, which can have direct effect on cellular and tissue function. In addition to uremia-specific 40 
causes such as abnormalities in the phosphate- Klotho axis, there are remarkable similarities 41 
between the pathophysiology of uremic inflammation and so-called “inflammaging” in the general 42 
population.  Potentially relevant, but still somewhat unexplored in this respect are abnormal or 43 
misplaced protein structures as well as abnormalities in tissue homeostasis, which evoke danger 44 
signals through damage associated molecular patters (DAMPS) as well as the senescence associated 45 
secretory phenotype (SASP). Systemic inflammation, in combination with the loss of kidney function, 46 
can impair the resilience of the body to external and internal stressors by reduced functional and 47 
structural tissue reserve, and by impairing normal organ crosstalk, thus providing an explanation for 48 
the greatly increased risk of homeostatic breakdown in this population. In this review, the relation 49 
between uremic inflammation and a premature aging phenotype, as well as potential causes and 50 
consequences are discussed.  51 
 52 
  53 
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Introduction 54 
End-stage renal disease (ESRD) is characterized by a greatly increased risk of cardiovascular and 55 
infectious mortality, as well as by structural and functional abnormalities of various organ systems, 56 
most notably the cardiovascular, the immune, and the musculoskeletal system. Substantial 57 
similarities in phenotype exist between ESRD and the aging process. About 30-50% of pre-dialysis, 58 
hemodialysis (HD), and peritoneal dialysis (PD) patients have serologic evidence of an active 59 
inflammatory response that is related to adverse outcomes (17, 18, 132). Persistent “uremici 60 
inflammation”, as this phenomenon has been coined in the literature (148),  resembles that observed 61 
in various chronic diseases as well as in the aging process in the general population (“inflammaging”).  62 
(68, 137).  63 
Although several reviews already have addressed the causes and nature of uremic 64 
inflammation in detail (18, 60, 132), recent findings have revealed novel causes and mechanisms of 65 
uremic inflammation as well as the catalytic role of systemic inflammation changing the risk factor 66 
profile. Since systemic inflammation may be both a cause and consequence of (premature) aging this 67 
may be of relevance for the marked discrepancy between chronological and biological age observed 68 
ESRD (68, 137). The aim of this review is to discuss potential similarities between the 69 
pathophysiology of inflammaging and systemic uremic inflammation, as well as on the putative 70 
relation between uremic inflammation and premature aging.  71 
 72 
Mechanisms of uremic inflammation 73 
Premature aging of the immune system 74 
The immune system is a complex orchestration of cells, cytokines and other molecules that act in a 75 
paracrine, autocrine, or endocrine manner to protect the human organism primarily against 76 
infectious disease (114). Whereas this mechanisms is essential for survival, when chronically 77 
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stimulated, it can become maladaptive and is in this sense an example of antagonistic pleiotropy 78 
(142). In the uremic milieu, abnormalities in the immune response are characterized by an abnormal 79 
activation and a reduced functioning of components of the innate and adaptive immune system, 80 
which contributes to systemic inflammation and increased susceptibility for infectious complications 81 
(58). Various abnormalities, such as an impaired neutrophilic phagocytic capacity, depletion of B-cells 82 
and naïve T-cells as well as depletion of dendritic cells contribute to reduced functioning of the 83 
immune system  (“immunosenescence”)  (8, 58, 155).  Important similarities exist between the 84 
effects of aging and ESRD on the adaptive immune response (8, 9), whereas a comparable systemic 85 
activation of the innate immune response may also be observed during aging (“inflammaging”) (68). 86 
Both factors argue for a premature aging process of the uremic immune system (9). 87 
Activation of the innate immune system 88 
The activation of the innate immune system in uremia is characterized by an increase in pro-89 
inflammatory cytokines, such as TNF and interleukin (IL)-6. Activation of transmembranous Toll-like 90 
receptors (TLR4), classically by pathogen-associated molecular patterns (PAMPS), induces 91 
transcription factors, such as nuclear factor-κB (NFκB) (89, 96), which is a master regulator of 92 
cytokine secretion. Moreover, IL-6 stimulates hepatic C-reactive protein (CRP) production (28). 93 
Importantly, NFκB is also upregulated by oxidative stress, and can be stimulated by cytokines, such as 94 
TNF, leading to self-stimulation of the inflammatory process (116) [Figure 1].  95 
NLPR (NACHT, LRR and PYD domains-containing protein) inflammasomes form another class of 96 
pattern recognition receptors (PRR). These lead to upregulation of IL-1B and IL-18 expression through 97 
caspase 1. Inflammasomes are intracellular protein complexes, which are activated by a variety of 98 
triggers, including cytokines, reactive oxygen species (ROS) as well and damage-associated molecular 99 
patterns (DAMPS) (76) [Figure 1]. An increase in NLRP3 mRNA expression, as well as upregulation of 100 
caspase 1, IL-1B and IL-18 was observed in peripheral blood mononuclear cells of HD patients 101 
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compared to controls (42). Whereas circulating myeloid cells and M1 macrophages are the primary 102 
effector cells of uremic inflammation (42), the inflammatory response can also be triggered in other 103 
cell types, such as vascular endothelium and vascular smooth muscle cells (14, 42, 89, 147). 104 
Defective regulation of the inflammatory process  105 
The inflammatory process is, under physiological circumstances, meticulously regulated, with an 106 
intricate balance between pro- and anti-inflammatory parameters (135). For the regulation of innate 107 
immune system, the sirtuin family, and most notably Sirtuin-1, plays an important role, modulated by 108 
Nf-kB inhibition through different pathways, such as AMPK, PGC-1 and PPAR (160). Sirtuin-1 down-109 
regulation may also lead to an imbalance between M1 pro-inflammatory and M2 anti-inflammatory 110 
macrophages in favor of the former. Sirtuin-1 downregulation has been observed in aging and 111 
metabolic syndrome and relates to inflammatory markers (59). Reduced sirtuin 3 expression also 112 
relates to mitochondrial damage and increased oxidative stress in animal models of acute kidney 113 
injury (102). Noteworthy in this context are recent observations indicating that at least two miRNAs 114 
(hsa-mir-217 and hsa-mir-125b) regulate sirtuin and AKT activity, as well as the mTOR pathways 115 
involved in regulating aging processes across taxa (91), providing a biochemical link between cellular 116 
ageing, stress and damage responses. Although its role in the pathogenesis of uremic inflammation 117 
needs to be established hsa-miR-125b is a critical component of a range of immunological 118 
phenomena, including host-defense responses, autoimmunity, immune cell differentiation and IL-4 119 
and INF-ƴ expression (145). A study using genome-wide gene expression profiling identified a 120 
differential expression of 80 genes between 10 hemodialysis (HD) patients and controls; variations of 121 
these genes are linked to pro-inflammatory pathways, such as the TLR pathways. Using interaction 122 
network analysis, 68 differentially expressed miRNA were connected to 47 genes suggesting an 123 
important role for miRNA in the regulation of uremic inflammation (170). 124 
 125 
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Arguments for a premature aging process in ESRD in relation to systemic inflammation  126 
The first argument for an uremic premature aging process is the increase in age-adjusted mortality, 127 
which is an aspecific marker of ageing. A recent editorial argued against the indiscriminate use of the 128 
term premature aging and proposed four domains of the aging phenotype (87) i.e. 1) changes in 129 
body composition, 2) impaired energy balance, 3) impaired homeostatic mechanisms and 4) 130 
neurodegeneration. A reduced lean tissue mass mass and an increase in fat mass (sarcopenic 131 
obesity) have been reported in ESRD (85, 86); both relate to the expression of inflammatory markers 132 
(50).  A low bone density is another prevalent feature of ESRD that relate to inflammation and 133 
adverse outcomes (22). Regarding energy balance, both maximum aerobic excercise as well as tissue 134 
glucose uptake are reduced in CKD (20, 153). While energetic efficiency appears to be reduced, 135 
resting energy expenditure are increased in ESRD, in relation to inflammation (158). Also, there is an 136 
inverse relation between physical activity (or physical capacity) with inflammatory markers (33). 137 
Except from anemia with high erythropoietin, the impaired homeostatic mechanisms mentioned by 138 
Margolick and Ferrucci (87) are all prevalent in uremic inflammation (68, 137). Notably, in keeping 139 
with these feautures, neurodegeneration, impaired cognitive function and balance are already 140 
prevalent in earlier stages of CKD (44, 88), whereas brain atrophy is a well known complications of 141 
ESRD (32). Next to these four domains, vascular progeria is a common finding in the inflamed uremic 142 
phenotype and significant associations between vascular calcification and increased vascular stiffness 143 
with inflammatory biomarkers are often reported (68). Thus, according to the phenotypic criteria, it 144 
can be concluded that an argument for the presence of a premature aging syndrome can be well 145 
made. Moreover, recent studies found that abnormalities in the kidney and blood vessels in patients 146 
with renal failure were associated with a progeric and senescent phenotype (138, 143).  147 
Mechanistic relations between uremic inflammation and (premature) aging  148 
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The next question is whether uremic inflammation is mechanistically related to biological ageing 149 
(174). For this purposes, a reflection on the relation between uremic inflammation and aging 150 
hallmarks is relevant (80). In non-uremic mice, chronic inflammation, induced by the knockout of the 151 
NFκB subunit 1, resulted in telomere shortening and a phenotype of progressive aging (56). In dialysis 152 
patients, increased telomere attrition was observed in comparison to age-matched controls and 153 
related to inflammatory markers (19, 24, 68). Oxidative stress, generally regarded as a major 154 
contributor to biological ageing, is increased in ESRD and reciprocally related to (uremic) 155 
inflammation (140, 172). Uremic inflammation impairs nutrient sensing, which is also considered an 156 
important hallmark of aging (80). TNF and IL-6 induce catabolism by stimulation of the ubiquitin 157 
proteasome complex and blunt anabolic pathways by IGF resistance and abberrant mTOR regulation 158 
(39, 68, 135). These effects, which can be considered a cellular stress response, can explained both 159 
by a direct effect of inflammation on these pathways. An alternative explanation is reduced energy 160 
availability to the cell because of shifting of energy to the inflammatory response and a concomitant 161 
increase in sympathetic nervous system activity (142). Moreover, systemic inflammation is also 162 
related to a decrease in endothelial progenitor cells in uremic patients (49). This might play a role in 163 
impaired vascular repair, although in the same study no link between endothelial progenitor cells 164 
and endothelial dysfunction was observed (106). A recent study by Kramann et al (70) show that 165 
critical adventitial progenitors (Gli1+ cells) may be relevant therapeutic targets for mitigation of 166 
vascular calcification. Senescence may also make the cell more susceptible to damage evoked by 167 
uremic toxins and or oxidative stress (16). 168 
 Causes of uremic inflammation  169 
Abnormalities in mineral metabolism 170 
Abnormalities in mineral metabolism appear to be another important link in the relation between 171 
inflammation and progeria (75). In adenine-induced CKD rats, dietary phosphate increased systemic 172 
TNF as well as tissue (e.g. in kidney heart and aorta) mRNA expression in a dose dependent matter, 173 
8 
 
which was prevented by the use of the phosphate binder lanthanum carbonate (166). In CKD4 174 
patients the phosphate binder sevelamer increased fetuin-A, which is a negative acute phase protein 175 
and an inhibitor of extracellular matrix mineralization) (139) (45) (15). The mechanisms behind 176 
phosphate-induced inflammation may at least be partly dependent upon generation of oxidative 177 
stress and activation of NFκB (175). Phosphate may also lead to osteoblast induction of vascular 178 
smooth muscle cells (VSMC), which might subsequently release inflammatory mediators especially in 179 
combination with a senescent phenotype (7). Indeed, increased serum phosphate levels may drive 180 
cellular and physiological senescence (73). A surprising result was observed in a study in uremic rats, 181 
where the calcification process of dietary phosphate was actually enhanced by a very low protein 182 
diet, and was also associated with systemic inflammation, as evidence by an increase in TNF levels 183 
and a decline in fetuin levels (167). Another proof linking phosphate to progeria is a recent study that 184 
reports that inorganic phosphate activate the mTOR pathway (57).  185 
Fetuin mediates the formation of calciprotein particles (CPP), circulating colloidal complexes 186 
containing calcium and phosphate, which are catabolized by the mononuclear phagocytic system 187 
(130) and might lead to a reduction of mineral stress. However, formation of CPP also results in the 188 
reduction of circulating and intracellular fetuin levels, with a potential loss of protection against the 189 
extracellular calcification and to the transformation of VSMC (128). The calcification propensity of 190 
serum, which is inversely reflected by the “maturation time” (T50) of CPPs, of serum was related to 191 
all-cause mortality in patients with CKD stages 3-4 as well as in renal transplant recipients (61, 129). It 192 
can be speculated that when formation of CPP exceeds clearance, the cytotoxic CPP induce pro-193 
inflammatory cytokines (130).  194 
Defective anti-aging mechanisms 195 
An intriguing relation appears to exist between uremic inflammation and the anti-aging protein 196 
Klotho (105). The anti-aging properties of Klotho in endothelial cells were explained by inhibition of 197 
NFκB translocation from cytoplasm to the nucleus by stabilisation of the NFκB /IKK complex, which 198 
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protected these cells from senescence (13). Klotho expression was reduced by TNF, TWEAK and NFκB 199 
activation (101, 142). Next to this epigenetic repression of Klotho gene expression via accumulation 200 
of protein bound toxins may be operative (144). As Klotho is also a potent inhibitor of vascular 201 
calcification, a self-reinforcing interaction between uremic inflammation, phosphate accumulation, 202 
decreased Klotho expression, cellular senescence, and vascular calcification may be operative in the 203 
uremic milieu (51). 204 
Gut dysbiosis  205 
The causes of inflammation specifically related to dialysis treatment, such as vascular access, 206 
bioincompatibility of dialysis membranes contamination of dialysis solutions or the use of 207 
intravenous iron, have been summarized extensively in previous reviews (17, 34, 40) [Figure 2]. The 208 
same holds true for potentially modifiable factors, such as periodentitis (17, 40, 71, 72). An emerging 209 
factor with relevance for both inflammaging and uremic inflammation is gut dysbiosis (83) (110, 156). 210 
Shi et al. (125) observed bacterial DNA in 12 out of 52 ESRD patients and a correlation with CRP and 211 
IL-6 levels. Elevated endotoxin levels, which are related to bacterial DNA (125), have also been 212 
observed in uremic plasma (93) and soluble CD14 predicts mortality in HD patients (109). Morever, 213 
the microbial metabolite Trimethylamine-N-oxide (TMAO), which has been linked to adverse 214 
cardiovascular outcome, correlates with uremic inflammation and is an independent predictor of 215 
mortality in CKD (99). Although the origin of the increased endotoxin levels in uremia remain to be 216 
elucidated it is likely that a translocation of gut microbiome due to increased gut permeability is the 217 
primary contributor. Constituents of tight junctions like claudin-1, occludin and ZO-1 were reduced in 218 
the colon of uremic rats (157). A recent study showed that depletion of tight junction proteins 219 
coincided with a reduction in nuclear factor erythroid 2-related factor 2 (Nrf2), which has a central 220 
role in the regulation of intracellular oxidative stress (74). Recently, a study studied the interaction of 221 
gut dysbiosis, aging and inflammation. In wild-type mice, the microbial constitution of the faeces, 222 
changed with aging whereas gut permeability  increased, leading to translocation of bacterial 223 
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products into the blood and induction of systemic inflammation. Remarkably, these age-related 224 
changes were absent in TNF-α deficient mice, which was explained by an interaction between the 225 
inflammatory state of the host and the intestinal microbiome (150)  226 
Regulation of oxidative stress  227 
Uremic toxins such as phosphate, protein bound toxins and advanced glycation end (AGEs) products, 228 
can evoke inflammatory pathways directly or mediated by oxidative stress (47). ROS stimulates the 229 
inflammatory process through NFκB signaling (78). As the uremic milieu may down-regulate Nrf2 230 
(107), which inhibits NFκB and upregulates a large number anti-oxidative genes (90), impaired Nrf2 231 
activity likely contributes to uremic inflammation. Perturbed expression of these expression factors 232 
also appears to contribute to senescence(176).  233 
Non-enzymatic glycation  234 
During the ageing process, increased protein damage takes place as a result of non-enzymatic 235 
glycation (108). Protein glycation was viewed originally as a post-translational modification of 236 
proteins that accumulated slowly on extracellular and long-lived proteins throughout life. In the 237 
extracellular matrix, so called advanced glycation endproducts (AGEs) caused aberrant cross-linking 238 
resulting in a decrease of elasticity in vessels leading to arterial stiffness and hypertension, i.e. 239 
hallmarks of vascular ageing. The physiological consequences of the formation of AGEs in the 240 
aetiology of a range of important age-related diseases, such as ESRD, have been described (82). In 241 
addition to the slow formation of AGES,  glycation adducts are also formed in a fast manner on 242 
cellular and short-lived extracellular proteins and on DNA. The highly reactive methylglyoxal (MG) is a 243 
key compound involved in the very fast generation of glycation adducts on proteins, lipids and DNA. 244 
Methylglyoxal is mainly generated as a by-product of glycolysis. To counteract the deleterious effects 245 
of MG, organisms contain an enzymatic glyoxalase defense system comprised of glyoxalase I (GLO1) 246 
and GLO2, in which MG is converted to D-lactate. GLO1 is a key enzyme in regulating the levels of 247 
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MGO and AGEs. It has been shown that GLO1 and GLO2 activity decreases in human arterial tissues 248 
and red blood cells during the aging process (63, 94). The downstream consequences of GLO1 249 
reduction have been demonstrated by an overexpression of the GLO1 homologue in C. Elegans, 250 
resulting in an increase of the mean and maximum lifespan by ca 30%; silencing the GLO1 homologue 251 
decreased the lifespan by about 50% (100, 122). Thus, since the balance between the production of 252 
MGO and its detoxification by GLO1 contribute to the ageing process, managing this balance is 253 
important for the prevention of age-related health problems (164). Next to their direct effects on the 254 
(vascular) aging process, AGEs can also induce inflammation via NFkB activation and subsequent 255 
expression of pro-inflammatory cytokines (141) in target cells, such as VSMC. A relation between 256 
serum pentosidine levels and monocyte activation markers was observed in CKD (162). On the other 257 
hand, blockade of the RAGE receptor reduced oxidative stress and atherosclerosis in uremic mice, 258 
but not the mRNA expression of inflammatory mediators in aortic smooth muscle cells (11). AGEs 259 
could also contribute to inflammation by endoplasmatic reticulum (ER) stress  (90), which occurs 260 
when the demand for protein folding, a major task of the ER, exceeds capacity (31). ER stress may 261 
induce inflammation and cellular senescence by NfkB activation and increased translocation of Ca2+ 262 
into the cytosol (31, 79, 117, 123). It has also been demonstrated that uremic serum induces ER 263 
stress in human umbilical vein endothelial cells (HUVEC), via NFkB upregulation (171). 264 
Danger associated molecular patterns (DAMPS) 265 
An important factor in the pathogenesis of inflammaging with potential relevance for uremic 266 
inflammation is the presence of misplaced or misfolded molecules, which serve as so-called danger 267 
associated molecular patterns (DAMPS), which are non-microbial inducers of inflammation that are 268 
evolutionary strongly preserved. DAMPS signal cellular and tissue stress and might evoke an 269 
inflammatory response by TLRs, RAGE and/or inflammasomes (38). Various DAMPS have been 270 
identified with portential relevance for CKD, such as extracellular ATP, uric acid, S100 proteins and 271 
the high mobility group box 1 HMBG1 protein (77, 120). Whereas there is accumulating evidence for 272 
a role of DAMPS in the pathogenesis of localized inflammation in CKD (113), the evidence for a role 273 
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of DAMPS in the pathogenesis of systemic uremic inflammation is yet limited. However, an inverse 274 
relation between renal function and serum levels of HMBG1 (12) and a relation between serum 275 
levels of HMBG1 and TNF, IL-6 and CRP (177) have been reported.  276 
Accumulation of DAMPS may be related to a disturbance in autophagy (38, 77). Autophagy  serves to 277 
remove damaged intracellular organelles and to enable the recirculation of essential nutrients. 278 
Complex interactions exist between inflammation and autophagy, which may act as a double endged 279 
sword for the individual. On one hand, autophagy may eliminate inflammatory triggers by removal of 280 
DAMPS. On the other hand, whereas systemic inflammation may induce autophagy through a cellular 281 
stress response, autophagy may also release DAMPS and, thus, induce inflammation (77, 118, 119). 282 
Similar to oxidative stress and inflammation, autophagy may be beneficial for cellular survival during 283 
short-term or minor insults, but have detrimental effects during prolonged or excessive activation. 284 
Reduced autophagy was observed in uremic leukocytes (21). However, autophagy of phosphate 285 
loaded VSMC was found to be protective against vascular calcification (25). Conversely, in an 286 
experimental model of renal failure, inflammation markers were related to increased autophagy in 287 
muscle (159). Thus it is not yet clear if increased or defective autophagy is a causative factor in 288 
uremic inflammation (161). 289 
Cellular senescence  290 
A factor which is considered highly important in the pathogenesis of inflammaging is the senescence-291 
associated secretory phenotype (SASP), in which senescent cells release pro-inflammatory cytokines 292 
such as TNF, IL-1, IL-6 and IL-8 (23) (112), which poison the surrounding tissues. The inflammatory 293 
process can progress from the cell to the tissue and whole body environment by extracellular 294 
spillover and through what is termed the communicome or secretome, which can act at local, tissue, 295 
as well as systemic levels. In this communicome, circulating cytokines, miRNA and extracellular 296 
vesicles may be involved (38). Senescent mononuclear cells with increased expression of pro-297 
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inflammatory cytokines were observed in HD-patients treated with cellulosic membranes, but not in 298 
serum of predialysis patients (111). Additionally, phosphate and indoxyl sulphate induce VSMC 299 
senescence (103, 165). VSMC in human carotid plaques of non-uremic patients showed evidence of a 300 
SASP accompanied by secretion of IL-1a (41). Studies on the SASP in CKD are limited. Although it has 301 
been suggested that the SASP is involved in the pathogenesis of chronic allograft nephropathy (131) 302 
the role of SASP in the pathogenesis of the uremic phenotype needs to be addressed further. We 303 
recently showed that severe uremic arterial calcification was associated with increased vascular 304 
expression of CDKN2A/p16INK4a, increased number p16 positive cells and SASP (138). Notably, in an 305 
epidemiological cohort, <10% of the variability in IL-6 expression in the circulation could be explained 306 
on the basis of cellular ageing, expressed by telomere length (127). A recent study showed that 307 
FOXO4 is elevated in senescent cellls and maintains their viability by preventing p53-induced 308 
apoptosis. Inhibition of the interaction between FOXO4 and p53 by a modified peptide (FOXO4-DRI 309 
[D-retro-invero] resulted in p53 induced apoptosis of senescent cells but also improved fitness, fur 310 
density and renal function in both naturally aged mice, as well as in a premature aging (XpdTTD/TTD) 311 
model (4). Whether substances like FOXO4-DRI could also have an impact on cellular senescence in 312 
the uremic phenotype should be investigated in future studies.  313 
 A special type of cellular senescence, which may contribute to uremic inflammation, is 314 
immunosenescence of the adaptive immune system. An increase in pro-inflammatory CD4+ CD28- 315 
effector cells and an imbalance of the Treg/TH17 cell ratio, simulating immunosenescence, has been 316 
detected in uremic serum (8, 26, 173). CD4+ CD25+ FoxP3 Treg cells have an inhibiting effect on 317 
systemic inflammation by releasing anti-inflammatory cytokines, such as IL-10 and TGF-. Since a 318 
relation was observed between CRP and IL-6 with and TH17 frequency and an inverse relation was 319 
observed between these factors and Treg frequency, a role for Treg/TH17 dysregulation in the 320 
pathogenesis of uremic inflammation could be suggested (173). It has also been reported that p-321 
cresyl sulfate induces macrophage activation and interfere in antigen processing, which lead to a 322 
failure in the uremic adaptive immune response (3). A consequence of vascular cellular senescence, 323 
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which could potentially be of major relevance in uremia, is breakdown of the blood brain barrier 324 
(168). Potentially, this could contribute to passage of retained cytokines and uremic toxins from the 325 
circulation to the brain and promote cognitive dysfunction, anorexia, and depression; all common 326 
features of the uremic phenotype (36).  327 
Abnormalities in tissue homeostasis  328 
Abnormalities in tissue homeostasis can also contribute to uremic inflammation following the 329 
concept of “para-inflammation” (95). One important potential trigger of uremic inflammation resides 330 
in visceral adipose tissue. Many ESRD patients show characteristics of “obese sarcopenia”; i.e. a 331 
progressive increase in fat mass and a decline in lean tissue mass commonly associated with 332 
inflammation (50, 85). The relative increase in (visceral) fat mass may contribute to uremic 333 
inflammation (2) via pro-inflammatory adipokines, like leptin and visfatin. However, a recent 334 
observational study has actually paradoxically shown a protective effect for  higher BMI levels in 335 
inflamed, but not in non-inflamed dialysis patients, showing the complexity and reverse causation of 336 
pathophysiologic relations that are operative in wasted and inflamed ESRD patients (133).  337 
Abnormalities in fluid or sodium composition of the extracellular tissue could also contribute to 338 
uremic inflammation. A relation between extracellular fluid overload and inflammation, as evidenced 339 
by CRP or IL-6 levels has been observed in various studies in both HD- and PD-patients  (30, 37, 52, 340 
66). Moreover, in accordance with the theory of catalytic effects of inflammation (18) the combined 341 
presence of fluid overload and inflammation was associated with a multiplicative risk of mortality as 342 
compared to the presence of fluid overload or inflammation in isolation (29). The mechanisms 343 
behind the relation between fluid overload and inflammation can theoretically be explained either by 344 
increased translocation of endotoxins or gut microbes or microbial fragments across an oedematous 345 
bowel wall (i.e. leaky gut), or by a progressive decline in lean tissue mass due to sustained 346 
inflammation, or by translocation of fluid from the vascular to the interstitial compartments, which 347 
may hamper removal during dialysis (29, 55). 348 
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There is an accumulation of osmotically interchangeable sodium not only in dialysis patients, but also 349 
in patients with non-uremic ageing or uncontrolled hypertension (151). The sodium concentration in 350 
this compartment has been estimated to be around 40 mmol/l greater than measured in plasma (10). 351 
Accumulation of interstitial sodium may act pro-inflammatory by stimulation of monocytes, and 352 
induction of IL-17-producing CD4+ T helper (Th17) cells, which may lead to systemic inflammation 353 
(64). In addition, sodium chloride inhibited the activation of IL-4 and IL-13 stimulating M2 (anti-354 
inflammatory) macrophages (10), as well the suppressive function of FOXP3+ regulatory T cells (46). 355 
The antibacterial effects of sodium and may be an evolutionary conserved mechanism for 356 
antimicrobial skin defense (53). However, whether interstitial sodium accumulation contributes to 357 
persistent inflammation and/or has a causal role in the pathogenesis of premature ageing in CKD has 358 
not yet been definitely established.  A last putative factor contributing to uremic inflammation is 359 
tissue hypoxia. Studies in healthy subjects have shown activation of the innate immune system, as 360 
reflected by an increase in IL-6 and CRP, as well as by an increase in natural killer cells in response to 361 
hypoxia (43, 65). Recent evidence indicates that HD-patients suffering from prolonged intradialytic 362 
hypoxemia, a condition defined as arterial oxygen saturation levels ≤90% for more than 1/3 of the 363 
treatment time, exhibit a pro-inflammatory phenotype (98). Low arterial oxygen saturation, anemia, 364 
and low cardiac output are frequently concurrently present in HD patients and may put tissues at an 365 
increased risk for hypoxia. Hypoxia triggers adaptive processes in all nucleated cells. HIF-1 mediates 366 
the expression of glycolytic enzymes and a switch from oxidative to glycolytic metabolism. This 367 
metabolic change results in an increased formation of superoxide, hydrogen peroxide and other toxic 368 
ROS (35, 124). HIF regulates an array of processes associated with the immune response and the host 369 
response to infection; in particular HIF plays a key role in the activities of T cells, B cells, dendritic 370 
cells, macrophages, and neutrophils. Members of the NFκB family regulate inflammation and interact 371 
with members of the PHD (prolyl hydroxylase domain)–HIF pathway in ways that link inflammation to 372 
hypoxia (121). Taken together, given the pro-inflammatory effects of local and systemic hypoxia and 373 
given the novel data there is a distinct possibility that hypoxemia may play a role in the genesis of the 374 
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pro-inflammatory uremic phenotype. Emerging data link tissue hypoxia to both mitochondrial 375 
dysfunction and inlamed uremic fat (134). Since data from a rodent model of programmed 376 
cardiovascular dysfunction link hypoxic pregnancy and oxidative stress to endothelial dysunction, 377 
inflammation and premature aging (1) more research is needed in this area. Lastly, systemic factors 378 
such as depression, as well as socioeconomic and psychosocial factors and associated epigenetic 379 
preconditioning, may contribute to uremic inflammation (92), although it is not yet exactly clear to 380 
which extent [Figure 1].  381 
 382 
Systemic effects of uremic inflammation  383 
Systemic low-grade inflammation is considered to be a cause of premature aging not only in CKD, but 384 
also in other chronic diseases such as chromnic obstructive pulmonary disease (COPD), congestive 385 
heart failure (CHF), rheumatoid arthritis (RA) and HIV (6, 104, 115, 154). In the previous paragraphs, 386 
we have explored to which extent chronic inflammation resembles “inflammaging” in the general 387 
population. We outlined how inflammation can contribute to cellular damage as well as activation of 388 
cellular stress resistance mechanisms. This can lead to effects in various organ system by a variety of 389 
changes, such as endothelial dysfunction, vascular calcification, increased vascular stiffness, left 390 
ventricular diastolic dysfunction, osteoporosis, cognitive dysfunction and muscular atrophy (68, 137, 391 
149).  392 
The long-term cumulative effects could lead to various clinical syndromes. The most well known are 393 
the malnutrition, inflammation and atherosclerosis (MIA) syndrome (17), and the frailty syndrome 394 
[Figure 3], defined by loss of lean tissue mass and muscle weakness as well as a reduced functional 395 
capacity, (54). Although the relation between biomarkers of aging and these different phenotypes 396 
has not been assessed yet, it is likely that these can be considered a subset of a premature ageing 397 
syndrome.  Systemic inflammation could also impair the homeostatic balance of the body in various 398 
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ways. The first is an impaired functioning and reduced structural reserve of cells and vital tissues by 399 
direct damage, by mitochondrial dysfunction, or by relocation of free energy for cellular maintenance 400 
and repair to the immune system (142, 146). Secondly, systemic inflammation could also impair 401 
homeostasis by influencing regulatory networks of the body. Homeostasis depends on a smooth 402 
information transfer at all levels; from individual cells to supersystems (163). Systemic inflammation 403 
may impair the normal homeostatic fine regulation through the communicome after extracellular 404 
spillover of cytokines as well as by an abnormal sympathocovagal balance (38) (152), thus prioritizing 405 
the inflammatory response over normal homeostatic regulation, as well as inducing allostatic load.  406 
Concluding, systemic inflammation can lead to a reduced structural and functional reserve as well as 407 
impaired regulatory mechanisms, resulting in reduced resilience to internal and external stressors.  408 
This occurs in combination with the loss of kidney function, which  cannot be fully replaced by 409 
contemporary dialysis techniques, and with comorbidities. Together, this could provide an 410 
explanation for the greatly increased risk of morbidity and mortality in ESRD (67) and, metaphorically 411 
stated, for an acceleration of biological time (69, 169). 412 
 413 
Outlook  414 
Whereas persistent systemic inflammation appears to be a major contributor to adverse outcomes as 415 
well as progeria in ESRD, it is not an inevitable consequence of reduced renal function. Indeed, a 416 
significant proportion of patients with ESRD have either normal or varying levels of inflammatory 417 
markers (97). Next to further investigations of reversible causes of uremic inflammation, it is also of 418 
relevance to try to identify patients that are protected from inflammation. Following the example of 419 
respiratory medicine (48), “endotyping” of CKD patients, by which detailed phenotypes are coupled 420 
to (epi)genetic variants and other biomarkers, could shed more light on both pro-inflammatory as 421 
well as protective mechanisms, and their relation to a premature ageing phenotype. There is a great 422 
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opportunity for collaboration between basic as well as clinical reseachers on this topic, because, as 423 
also shown in this review, the study of uremic inflammation is relevant at all system levels in the 424 
body, from (epi)genetics to phenotype. This provides indeed the opportunity to connect these 425 
different system levels in order to identify central mechanisms which are ideally also amendable for 426 
therapeutic interventions.       427 
However, given the multidimensional causality of uremic inflammation, it is unlikely that a single 428 
therapeutic “magic bullet” will ever be identified. Recent reviews (81, 136) summarized five 429 
therapeutical concepts, which could be applied to combat inflammation in ESRD. The first is to 430 
identify and treat underlying sources of inflammation. The second is to promote healthy dietary 431 
habits and lifestyle changes that include low-intensity exercise programs (84). Third, in an 432 
experimental setting, pharmacological interventions developed to combat inflammation in other 433 
chronic diseases as well as, fourth, anti-cytokine treatments may also be applied in ESRD considered 434 
not at increased risk for infectious complications. Finally, as recent data imply that elimination of 435 
p16INK4a positive cells improve health span in mice (5), senolytic drugs, such as dasatinab and 436 
qurecetin, should be tested in conditions in which senescence may contribute to disease 437 
pathogenesis, such as ESRD. Next to interventions specifically focusing on inflammation, it is also of 438 
major importance to increase the resilience of the body by physical activity and adequate diet, next 439 
to reducing end organ damage due to allostatic overload by factors other than inflammation, e.g. by 440 
adequate fluid and blood pressure control and adequate dialysis technique. 441 
Despite the huge potential of the approaches mentioned above (27), few controlled studies have 442 
proven success in the management of oxidative stress or systemic inflammation in the uremic milieu. 443 
It is of important to realize that targeted mechanisms may have pleiotropic effects (62), or that 444 
targeted interventions might focus on pathways, which are influenced by multiple other factors (41). 445 
In the future, it is likely that these pitfalls can be partly avoided by the further elucidation of pro- and 446 
anti-inflammatory pathways. Since inflammatory biomarkers are “moving targets”, randomized 447 
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controlled trials need to include large number of patients in each arm in order to provide sufficient 448 
power to prove any anti-inflammatory effect of various interventions. Moreover, given the strong 449 
interaction between inflammation and the progeric process (“inflammaging”) it is likely that 450 
interventions developed in the gerontology field, or in other chronic diseases will also have relevance 451 
for CKD and vice versa (126).  452 
Conclusion 453 
Important conceptual similarities exist between uremic inflammation and “inflammaging” in the 454 
general population. The native inflammatory system is based on a highly evolutionary preserved 455 
mechanism, which shows a common effector response to a variety of noxious stimuli. In this sense, it 456 
also shares important similarities with other chronic diseases, such as COPD, CHF, RA and HIV, 457 
although there are clearly disease specific phenotypical differences next to important similarities. It 458 
might therefore be hypothesized that uremic inflammation is an example of progressive “unhealthy” 459 
aging, both mechanistically as well as phenotypically. Thus, it could be speculated that age-related 460 
diseases could be treated more effectively by modulating fundamental mechanisms of aging per se, 461 
versus the attempt to prevent or delay organ-specific complications one at a time. Studies 462 
incorporating patients with different chronic diseases as well as aging subjects may shed more role in 463 
the relation between phenotypes and their underlying mechanisms and could provide an answer the 464 
question whether phenotypical alterations in these diseases are indeed an example of progressive 465 
unhealthy aging. This could in turn lead to shared and better treatment approaches for 466 
“inflammaging”.  467 
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Figure 1. Basic mechanisms of uremic inflammation 971 
Figure 2. Causes of uremic inflammation 972 
Figure 3. Inflammation concerns and consequences 973 
Figure 4. Effects of systemic inflammation on homeostasis   974 
                                                            
i In which uremia is defined as the medical condition produced by the toxic effects of abnormally high 
concentrations of nitrogenous substances in the blood as a result of the kidney’s failure to expel waste 
products by way of the urine (https://www.britannica.com/science/uremia) 




